Alixizumab needs to be administered by subcutaneous injection under the supervision of a medical professional. Aliximab is a fully human monoclonal antibody, and its use in adults diagnosed with atherosclerotic vascular disease can be effective in reducing the risk of stroke, myocardial infarction, and unstable angina requiring hospitalization, and it can also be used as an adjunctive therapy to diet in adults with primary hypercholesterolemia and mixed dyslipidemia to help patients lower their LDL cholesterol . ADVERSE REACTIONS: Common adverse reactions caused by aliskirenumab include pruritus, injection site reactions, and upper respiratory signs and symptoms. CONTRAINDICATIONS: Contraindications are required for those who are allergic to any of the ingredients contained in the drug. Precautions: If a severe allergic reaction occurs with the drug, it must be discontinued and treated with symptomatic therapy. The drug is injected subcutaneously into the abdomen, thighs or upper arms using a disposable prefilled injection pen. It should not be injected into the site of active skin diseases or injuries, and should not be injected into the same injection site at the same time as other injectable drugs. Individuals need to strictly follow the doctor’s instructions for the scientific and rational use of aliskirenzumab, and to inform the physician in time if there is any abnormality in the body after the use of the drug.